AB170922

Anti-FGL1 antibody [EPR9937]

KO Validated
RabMAb
Recombinant
What is this?

Be the first to review this product! Submit a review

(3 Publications)

Rabbit Recombinant Monoclonal FGL1 antibody. Suitable for IP, WB and reacts with Human samples. Cited in 3 publications.

View Alternative Names

HFREP1, FGL1, Fibrinogen-like protein 1, HP-041, Hepassocin, Hepatocyte-derived fibrinogen-related protein 1, Liver fibrinogen-related protein 1, HPS, HFREP-1, LFIRE-1

3 Images

Supplier Data

Immunoprecipitation - Anti-FGL1 antibody [EPR9937] (AB170922)

All lanes:

Immunoprecipitation - Anti-FGL1 antibody [EPR9937] (ab170922) at 1/1000 dilution

All lanes:

Immunoprecipitation pellet from Human fetal liver lysate using ab170922 at 1/10. at 10 µg

Secondary

All lanes:

Goat anti-rabbit HRP conjugated antibody at 1/2000 dilution

Predicted band size: 36 kDa

Observed band size: ~50 kDa

true

Lab

Western blot - Anti-FGL1 antibody [EPR9937] (AB170922)

Western blot : Rabbit Monoclonal [EPR9937] to FGL1 ab170922 staining at 1/1000 dilution, shown in green; Mouse anti alpha Tubulin ab7291 loading control staining at 1/20000 dilution, shown in magenta. A band was observed at 36 kDa. To generate this image, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3pc Milk in TBS-0.1 % Tween 20 (TBS-T) before incubation with primary antibodies overnight at 4 C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit 800CW and Goat anti-Mouse 680RD at 1/20,000 dilution.

All lanes:

Western blot - Anti-FGL1 antibody [EPR9937] (ab170922) at 1/1000 dilution

Lane 1:

Wild-type A549 IL-6 (5 ng/mL, 48 h) + BFA (5 g/mL, last 6 h) at 20 µg

Lane 2:

Wild-type A549 IL-6 (0 ng/mL, 48 h) + BFA (5 g/mL, last 6 h) at 20 µg

Lane 3:

Wild-type A549 BFA (0 g/mL, 6 h) at 20 µg

Lane 4:

FGL1 knockout A549 IL-6 (5 ng/mL, 48 h) + BFA (5 g/mL, last 6 h) at 20 µg

Lane 5:

FGL1 knockout A549 IL-6 (0 ng/mL, 48 h) + BFA (5 g/mL, last 6 h) at 20 µg

Lane 6:

FGL1 knockout A549 BFA (0 g/mL, 6 h) at 20 µg

Lane 7:

HepG2 at 20 µg

Lane 8:

HeLa at 20 µg

Secondary

All lanes:

Goat anti-Rabbit 800CW & Goat anti-Mouse 680RD at 1/20000 dilution

Predicted band size: 36 kDa

Observed band size: 36 kDa

false

Supplier Data

Western blot - Anti-FGL1 antibody [EPR9937] (AB170922)

All lanes:

Western blot - Anti-FGL1 antibody [EPR9937] (ab170922) at 1/1000 dilution

Lane 1:

Human fetal liver lysate at 10 µg

Lane 2:

HepG2 cell lysate at 10 µg

Secondary

All lanes:

Goat anti-rabbit HRP conjugated antibody at 1/2000 dilution

Predicted band size: 36 kDa

true

Carrier free

Anti-FGL1 antibody [EPR9937] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR9937

Isotype

IgG

Carrier free

Reacts with

Human

Applications

WB, IP

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/10 - 1/100", "IP-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/5000", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" }, "Mouse": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "1/10 - 1/100", "IP-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "1/1000 - 1/5000", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" }, "Rat": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "1/10 - 1/100", "IP-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "1/1000 - 1/5000", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }

style

left-column

Product details

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein A

Storage buffer

pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Fibrinogen-like protein 1 (FGL1) also known as Hepassocin plays a significant role in modulating immune responses. FGL1 is a member of the fibrinogen family with a molecular mass of approximately 31 kDa. This protein is widely expressed in the liver and is also found in other tissues like the pancreas and lungs. Its structural homology to fibrinogen suggests potential binding capabilities with similar ligands influencing its mechanical actions in cellular processes.

Biological function summary

FGL1 modulates the immune system and maintains its homeostasis. It functions primarily as a ligand for the immune checkpoint receptor LAG-3. This FGL1-LAG-3 interaction inhibits T-cell activity leading to immune tolerance and helping prevent autoimmunity. FGL1 while not a part of a complex demonstrates significant standalone biological activity by affecting immune responses especially under pathological conditions.

Pathways

FGL1 integrates into the immune regulatory framework. It exerts its effects mainly through the immune checkpoint pathway impacting T-cell regulation. In addition to LAG-3 FGL1 interacts closely with the PD-1/PD-L1 pathway which is also important in checkpoint inhibition and immune evasion mechanisms. These pathways together orchestrate the immune surveillance system and play roles in maintaining immune equilibrium.

FGL1 has received attention in cancer particularly in its role of suppressing anti-tumor immunity. Its interaction with LAG-3 makes it a potential target for cancer immunotherapy as high FGL1 levels correlate with poor prognosis in various cancers. Additionally it has implications in autoimmune diseases where its regulation of T-cell activity prevents excessive immune responses. By modulating LAG-3 activity FGL1 emerges as a therapeutic target of interest in autoimmune conditions presenting new opportunities for managing such disorders.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Immune suppressive molecule that inhibits antigen-specific T-cell activation by acting as a ligand of LAG3 (PubMed : 30580966, PubMed : 35761082, PubMed : 40101708). LAG3-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation (PubMed : 30580966). Binds LAG3 independently from MHC class II (MHC-II) (PubMed : 30580966, PubMed : 35761082). Secreted by, and promotes growth of, hepatocytes (PubMed : 11470158, PubMed : 19880967).

See full target information FGL1

style

left-column

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

Acta pharmacologica Sinica 45:1951-1963 PubMed38760543

2024

Bevacizumab induces ferroptosis and enhances CD8 T cell immune activity in liver cancer via modulating HAT1 and increasing IL-9.

Applications

Unspecified application

Species

Unspecified reactive species

Chun-Yu Hou,Pan Lv,Hong-Feng Yuan,Li-Na Zhao,Yu-Fei Wang,Hui-Hui Zhang,Guang Yang,Xiao-Dong Zhang

Frontiers in immunology 13:1014053 PubMed36268014

2022

Dual immunological and proliferative regulation of immune checkpoint FGL1 in lung adenocarcinoma: The pivotal role of the YY1-FGL1-MYH9 axis.

Applications

Unspecified application

Species

Unspecified reactive species

Xi-Yang Tang,Yan-Lu Xiong,Ya-Bo Zhao,Jie Yang,An-Ping Shi,Kai-Fu Zheng,Yu-Jian Liu,Chen Shu,Tao Jiang,Nan Ma,Jin-Bo Zhao

Human mutation 43:42-55 PubMed34816548

2021

GGCX variants leading to biallelic deficiency to γ-carboxylate GRP cause skin laxity in VKCFD1 patients.

Applications

Unspecified application

Species

Unspecified reactive species

Suvoshree Ghosh,Katrin Kraus,Arijit Biswas,Jens Müller,Francesco Forin,Heike Singer,Klara Höning,Veit Hornung,Matthias Watzka,Johannes Oldenburg,Katrin J Czogalla-Nitsche

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-FGL1 antibody [EPR9937]

Immunoprecipitation - Anti-FGL1 antibody [EPR9937] (AB170922)

Western blot - Anti-FGL1 antibody [EPR9937] (AB170922)

Western blot - Anti-FGL1 antibody [EPR9937] (AB170922)

Related conjugates and formulations (1)

Key facts

Host species

Clonality

Clone number

Isotype

Carrier free

Reacts with

Applications

Immunogen

Alternative Products

Primary Antibodies

Primary Antibodies

Complementary Products

Assay Kits

Secondary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Reactivity data

Product details

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage duration

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (3)

Product promise